Trial will evaluate efficacy of anti-netrin-1 antibody candidate NP137 in combination with Atezo-bev
Netris Pharma has dosed the first participant in the ImmunoNET Phase II trial of NP137 for immune-checkpoint inhibitor resistance.
LYON, France--(BUSINESS WIRE)--NETRIS Pharma, a clinical-stage private biopharmaceutical company developing a new class of drugs based on dependence receptor biology, today announced dosing of the first patient in the ImmunoNET trial. ImmunoNET is a multicenter, open-label, proof of concept phase II trial designed to assess the clinical and biological activity of NETRIS Pharma’s first drug candidate, NP137, as add-on therapy in patients with advanced/metastatic solid tumors treated by standard immunotherapies.